Target intelligence / Profile preview

Proteasome subunit beta type (PSMB)

Target
PSMB
Molecular classification
Enzyme, Protease (specifically, threonine protease), Component of the proteasome complex
01

Overview

Proteasome subunit beta type is a class of proteins that constitute the beta subunits of the 20S core proteasome complex, a large, multisubunit protease responsible for the ATP/ubiquitin-dependent degradation of intracellular proteins. The 20S core is a barrel-shaped assembly composed of four rings: two outer alpha rings and two inner beta rings, each containing seven subunits. Of the beta subunits, types 1, 2, and 5 (e.g., PSMB1, PSMB2, PSMB5) contain proteolytically active sites that confer different cleavage specificities (caspase-like, trypsin-like, chymotrypsin-like activities). These subunits are essential for regulated protein degradation, controlling cell cycle, apoptosis, and immune responses. Dysfunction or altered expression of these subunits is implicated in various disease processes, and selective inhibition of proteasome beta subunits (particularly beta type-5) has led to the development of clinically approved anti-cancer drugs.

Other names
Proteasome beta subunit20S proteasome beta subunitPSMB family20S proteasome subunit beta-6
02

Mechanism of action

Inhibition of proteasome activity (typically targeting the chymotrypsin-like activity of the beta type-5 subunit), leading to accumulation of ubiquitinated proteins, cell cycle arrest, and apoptosis

03

Biological functions

Protein degradation (ubiquitin-proteasome pathway)Protein quality controlAntigen processing (for MHC class I presentation)Regulation of cell cycleApoptosis
04

Disease associations

CancerNeurodegenerative diseaseInflammationAutoimmune diseaseCardiovascular disease
05

Safety considerations

Peripheral neuropathyMyelosuppression (cytopenias)Gastrointestinal toxicityIncreased risk of infections (due to immune modulation)
06

Interacting drugs

Bortezomib (Velcade)

4 more in the full profile.

07

Biomarkers

Proteasome activity or subunit expression levels (in cancer, particularly for predicting sensitivity to proteasome inhibitors)

Beyond the preview

Go deeper on Proteasome subunit beta type (PSMB).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Proteasome subunit beta type (PSMB).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call